These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A little innovation. Baylor launches biotech firm to sell cancer therapy. Barr P Mod Healthc; 2004 Nov; 34(46):20. PubMed ID: 15609730 [No Abstract] [Full Text] [Related]
7. Dendritic cells and T cells in immunotherapy. O'Neill DW J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761 [TBL] [Abstract][Full Text] [Related]
8. Listening to Provenge--what a costly cancer treatment says about future Medicare policy. Chambers JD; Neumann PJ N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004 [No Abstract] [Full Text] [Related]
9. Biotech plummets in 3Q11. Yang W Nat Biotechnol; 2011 Nov; 29(11):962. PubMed ID: 22068525 [No Abstract] [Full Text] [Related]
10. Therapy: An immune one-two punch. Bourzac K Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788 [No Abstract] [Full Text] [Related]
11. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
12. David Urdal. Interview with Asher Mullard. Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031 [No Abstract] [Full Text] [Related]
13. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Fishman M Expert Opin Biol Ther; 2009 Dec; 9(12):1565-75. PubMed ID: 19916735 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869 [No Abstract] [Full Text] [Related]
18. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
19. DCs in lymphoma--biology and therapeutic aspects. Schultze JL; Fiore F; von Bergwelt-Baildon M Cytotherapy; 2004; 6(2):138-47. PubMed ID: 15203990 [No Abstract] [Full Text] [Related]
20. Cellular immunotherapy licensed for advanced prostate cancer. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204 [No Abstract] [Full Text] [Related] [Next] [New Search]